Determination of Cotinine, 3′-Hydroxycotinine, and Their Glucuronides in Urine by Ultra-high Performance Liquid Chromatography

Analytical Letters

Volumn 48, Issue 8, 2015, Pages 1217-1233

  Shastri, Madhur D ^a   Lu, Wenying ^a   Ferguson, Stuart G ^a   Narkowicz, Christian K ^a   Davies, Noel W ^b   Jacobson, Glenn A ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

^b UNIVERSITY OF TASMANIA   (Australia)

Author keywords

3 hydroxycotinine; Cotinine; Glucuronide; Smoking; Ultra high performance liquid chromatography; Urine

Indexed keywords

EID: 84924955315     PISSN: 00032719     EISSN: 1532236X     Source Type: Journal    
DOI: 10.1080/00032719.2014.979363     Document Type: Article

References (39)

1. Benowitz, N. L. 1996. Pharmacology of nicotine: addiction and therapeutics. Annual Review of Pharmacology and Toxicology 36: 597–613. doi:10.1146/annurev.pharmtox.36.1.597
2. Benowitz, N. L., K. M. Dains, D. Dempsey, B. Herrera, L. Yu, and P. Jacob. 2009. Urine nicotine metabolite concentrations in relation to plasma cotinine during low-level nicotine exposure. Nicotine & Tobacco Research 11: 954–60. doi:10.1093/ntr/ntp092
3. Benowitz, N. L., P. Jacob, I. Fong, and S. Gupta. 1994. Nicotine metabolic profile in man: comparison of cigarette smoking and transdermal nicotine. Journal of Pharmacology and Experimental Therapeutics 268: 296–303.
4. Benowitz, N. L., E. J. Perez-Stable, I. Fong, G. Modin, B. Herrera, and P. Jacob. 1999. Ethnic differences in N-glucuronidation of nicotine and cotinine. Journal of Pharmacology and Experimental Therapeutics 291: 1196–203.
5. Benowitz, N. L., O. F. Pomerleau, C. S. Pomerleau, and P. Jacob. 2003. Nicotine metabolite ratio as a predictor of cigarette consumption. Nicotine & Tobacco Research 5: 621–24. doi:10.1080/1462220031000158717
6. Berg, J. Z., L. B. von Weymarn, E. A. Thompson, K. M. Wickham, N. A. Weisensel, D. K. Hatsukami, and S. E. Murphy. 2010. UGT2B10 genotype influences nicotine glucuronidation, oxidation, and consumption. Cancer Epidemiology Biomarkers & Prevention 19: 1423–31. doi:10.1158/1055-9965.epi-09-0959
7. Bernert, J. T., W. E. Turner, J. L. Pirkle, C. S. Sosnoff, J. R. Akins, M. K. Waldrep, Q. Ann, T. R. Covey, W. E. Whitfield, E. W. Gunter, B. B. Miller, D. G. Patterson, L. L. Needham, W. H. Hannon, and E. J. Sampson. 1997. Development and validation of sensitive method for determination of serum cotinine in smokers and nonsmokers by liquid chromatography/atmospheric pressure ionization tandem mass spectrometry. Clinical Chemistry 43: 2281–91.
8. Byrd, G. D., R. A. Davis, and M. W. Ogden. 2005. A rapid LC-MS-MS method for the determination of nicotine and cotinine in serum and saliva samples from smokers: validation and comparison with a radioimmunoassay method. Journal of Chromatographic Science 43: 133–40. doi:10.1093/chromsci/43.3.133
9. Chen, G., N. E. Giambrone, D. F. Dluzen, J. E. Muscat, A. Berg, C. J. Gallagher, and P. Lazarus. 2010. Glucuronidation genotypes and nicotine metabolic phenotypes: importance of functional UGT2B10 and UGT2B17 polymorphisms. Cancer Research 70: 7543–52. doi:10.1158/0008-5472.can-09-4582
10. de Beyer, J., C. Lovelace, and A. Yürekli. 2001. Poverty and tobacco. Tobacco Control 10: 210–11. doi:10.1136/tc.10.3.210
11. De Cremer, K., I. Van Overmeire, and J. Van Loco. 2013. On-line solid-phase extraction with ultra performance liquid chromatography and tandem mass spectrometry for the detection of nicotine, cotinine and trans-3′-hydroxycotinine in urine to strengthen human biomonitoring and smoking cessation studies. Journal of Pharmaceutical and Biomedical Analysis 76: 126–33. doi:10.1016/j.jpba.2012.12.018
12. Dempsey, D., P. Tutka, P. Jacob, F. Allen, K. Schoedel, R. F. Tyndale, and N. L. Benowitz. 2004. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clinical Pharmacology & Therapeutics 76: 64–72. doi:10.1016/j.clpt.2004.02.011
13. Derby, K. S., K. Cuthrell, C. Caberto, S. G. Carmella, A. A. Franke, S. S. Hecht, S. E. Murphy, and L. Le Marchand. 2008. Nicotine metabolism in three ethnic/racial groups with different risks of lung cancer. Cancer Epidemiology Biomarkers & Prevention 17: 3526–35. doi:10.1158/1055-9965.epi-08-0424
14. Dhar, P. 2004. Measuring tobacco smoke exposure: quantifying nicotine/cotinine concentration in biological samples by colorimetry, chromatography and immunoassay methods. Journal of Pharmaceutical and Biomedical Analysis 35: 155–68. doi:10.1016/j.jpba.2004.01.009
15. Dobrinas, M., E. Choong, M. Noetzli, J. Cornuz, N. Ansermot, and C. B. Eap. 2011. Quantification of nicotine, cotinine, trans-3′-hydroxycotinine and varenicline in human plasma by a sensitive and specific UPLC–tandem mass-spectrometry procedure for a clinical study on smoking cessation. Journal of Chromatography B 879: 3574–82. doi:10.1016/j.jchromb.2011.09.046
16. Hecht, S. S., S. G. Carmella, and S. E. Murphy. 1999. Effects of watercress consumption on urinary metabolites of nicotine in smokers. Cancer Epidemiology Biomarkers & Prevention 8: 907–13.
17. Ho, M. K., J. C. Mwenifumbo, N. Al Koudsi, K. S. Okuyemi, J. S. Ahluwalia, N. L. Benowitz, and R. F. Tyndale. 2009. Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. Clinical Pharmacology & Therapeutics 85: 635–43. doi:10.1038/clpt.2009.19
18. Hukkanen, J., P. Jacob, and N. L. Benowitz. 2005. Metabolism and disposition kinetics of nicotine. Pharmacological Reviews 57: 79–115. doi:10.1124/pr.57.1.3
19. ICH Harmonised Tripartite Guideline. 1994. Validation of analytical procedures: text and methodology Q2(R1): 11–12.
20. Jacob, P., A. T. Shulgin, and N. L. Benowitz. 1990. Synthesis of (3′R,5′S)-trans-3′-hydroxycotinine, a major metabolite of nicotine. Metabolic formation of 3′-hydroxycotinine in humans is highly stereoselective. Journal of Medicinal Chemistry 33: 1888–91. doi:10.1021/jm00169a009
21. Jacob, P., L. Yu, M. Duan, L. Ramos, O. Yturralde, and N. L. Benowitz. 2011. Determination of the nicotine metabolites cotinine and trans-3′-hydroxycotinine in biologic fluids of smokers and non-smokers using liquid chromatography-tandem mass spectrometry: biomarkers for tobacco smoke exposure and for phenotyping cytochrome P450 2A6 activity. Journal of Chromatography B 879: 267–76. doi:10.1016/j.jchromb.2010.12.012
22. Ji, A. J., G. M. Lawson, R. Anderson, L. C. Dale, I. T. Croghan, and R. D. Hurt. 1999. A new gas chromatography-mass spectrometry method for simultaneous determination of total and free trans-3′-hydroxycotinine and cotinine in the urine of subjects receiving transdermal nicotine. Clinical Chemistry 45: 85–91.
23. Kim, I., and M. A. Huestis. 2006. A validated method for the determination of nicotine, cotinine, trans-3′-hydroxycotinine, and norcotinine in human plasma using solid-phase extraction and liquid chromatography-atmospheric pressure chemical ionization-mass spectrometry. Journal of Mass Spectrometry 41: 815–21. doi:10.1002/jms.1039
24. Kuo, H. W., J. S. Yang, and M. C. Chiu. 2002. Determination of urinary and salivary cotinine using gas and liquid chromatography and enzyme-linked immunosorbent assay. Journal of Chromatography B 768(2): 297–303. doi:10.1016/s1570-0232(01)00613-4
25. Lerman, C., C. Jepson, E. P. Wileyto, F. Patterson, R. Schnoll, M. Mroziewicz, N. Benowitz, and R. F. Tyndale. 2010. Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy. Clinical Pharmacology & Therapeutics 87: 553–57. doi:10.1038/clpt.2010.3
26. Messina, E. S., R. F. Tyndale, and E. M. Sellers. 1997. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics 282: 1608–14.
27. Moolchan, E. T., C. S. Parzynski, M. Jaszyna-Gasior, C. C. Collins, M. K. Leff, and D. L. Zimmerman. 2009. A link between adolescent nicotine metabolism and smoking topography. Cancer Epidemiology Biomarkers & Prevention 18: 1578–83. doi:10.1158/1055-9965.epi-08-0592
28. Moyer, T. P., J. R. Charlson, R. J. Enger, L. C. Dale, J. O. Ebbert, D. R. Schroeder, and R. D. Hurt. 2002. Simultaneous analysis of nicotine, nicotine metabolites, and tobacco alkaloids in serum or urine by tandem mass spectrometry, with clinically relevant metabolic profiles. Clinical Chemistry 48: 1460–71.
29. Mwenifumbo, J. C., and R. F. Tyndale. 2007. Genetic variability in CYP2A6 and the pharmacokinetics of nicotine. Pharmacogenomics 8: 1385–402. doi:10.2217/14622416.8.10.1385
30. Nakajima, M., T. Yamamoto, K. Nunoya, T. Yokoi, K. Nagashima, K. Inoue, Y. Funae, N. Shimada, T. Kamataki, and Y. Kuroiwa. 1996. Characterization of CYP2A6 involved in 3′-hydroxylation of cotinine in human liver microsomes. Journal of Pharmacology and Experimental Therapeutics 277: 1010–15.
31. Pellegrini, M., E. Marchei, S. Rossi, F. Vagnarelli, A. Durgbanshi, O. Garcia-Algar, O. Vall, and S. Pichini. 2007. Liquid chromatography/electrospray ionization tandem mass spectrometry assay for determination of nicotine and metabolites, caffeine and arecoline in breast milk. Rapid Communications in Mass Spectrometry 21: 2693–703. doi:10.1002/rcm.3137
32. Rangiah, K., W.-T. Hwang, C. Mesaros, A. Vachani, and I. A. Blair. 2011. Nicotine exposure and metabolizer phenotypes from analysis of urinary nicotine and its 15 metabolites by LC–MS. Bioanalysis 3: 745–61. doi:10.4155/bio.11.42
33. Schnoll, R. A., F. Patterson, E. P. Wileyto, R. F. Tyndale, N. Benowitz, and C. Lerman. 2009. Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study. Pharmacological Biochemistry and Behavior 92: 6–11. doi:10.1016/j.pbb.2008.10.016
34. Shakleya, D. M., and M. A. Huestis. 2009a. Simultaneous and sensitive measurement of nicotine, cotinine, trans-3′-hydroxycotinine and norcotinine in human plasma by liquid chromatography-tandem mass spectrometry. Journal of Chromatography B 877: 3537–42. doi:10.1016/j.jchromb.2009.08.033
35. Shakleya, D. M., and M. A. Huestis. 2009b. Optimization and validation of a liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of nicotine, cotinine, trans-3′-hydroxycotinine and norcotinine in human oral fluid. Analytical and Bioanalytical Chemistry 395: 2349–57. doi:10.1007/s00216-009-3157-2
36. Tuomi, T., T. Johnsson, and K. Reijula. 1999. Analysis of nicotine, 3-hydroxycotinine, cotinine, and caffeine in urine of passive smokers by HPLC-tandem mass spectrometry. Clinical Chemistry 45: 2164–72.
37. Whitmire, M., J. Ammerman, P. de Lisio, J. Killmer, D. Kyle, E. Mainstone, L. Porter, and T. Zhang. 2011. LC-MS/MS bioanalysis method development, validation, and sample analysis: points to consider when conducting nonclinical and clinical studies in accordance with current regulatory guidances. Journal of Analytical & Bioanalytical Techniques. S4: 001. doi:10.4172/2155-9872.S4-001
38. Xu, X., M. M. Iba, and C. P. Weisel. 2004. Simultaneous and sensitive measurement of anabasine, nicotine, and nicotine metabolites in human urine by liquid chromatography–tandem mass spectrometry. Clinical Chemistry 50: 2323–30. doi:10.1373/clinchem.2004.038489
39. Zhu, A. Z. X., Q. Zhou, L. S. Cox, J. S. Ahluwalia, N. L. Benowitz, and R. F. Tyndale. 2013. Variation in trans-3′-hydroxycotinine glucuronidation does not alter the nicotine metabolite ratio or nicotine intake. PloS One. 8: e70938. doi:10.1371/journal.pone.0070938